Selected Publications

  1.  Bak RO*, Dever DP*, Reinisch A*, Cruz Hernandez D, Majeti R*, and Porteus MH*. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. eLife, 6; pii:e27873 (2017)
  2. McKeown MR*, Corces MR*, Eaton ML*, Fiore C*, Lee E, Lopez JT, Chen MW, Cmith D, Chan SM, Koenig JL, Austgen K, Guenther MG, Orlando DA, Loven J, Fritz CC, and Majeti R. Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RARa dependency targetable by SY-1425, a potent and selective RARa agonist. Cancer Discovery, 7: 1136-1153 (2017)
  3. Sinha S*, Thomas D*, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernards R, Majeti R*, and Dill DL*. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications, 8: 15580 (2017)
  4. Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, Xavy S, Shen J, Haag D, Chanda S, Sinha R, Morganti RM, Nishimura T, Ameen M, Wu H, Wernig M, Wu JC, and Majeti R. Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease. Cell Stem Cell, 20:329-344 (2016)
  5. Corces MR, Buenrostro J, Wu B, Greenside PG, Chan SM, Koenig JL, Snyder MP, Pritchard JK, Kundaje A, Greenleaf WJ, Majeti R*, and Chang H*. Lineage-specific and single cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nature Genetics, 48: 1193-1203 (2016)
  6. Jonas BA, Johnson C, Gratzinger D, and Majeti R. Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. PLoS One, 11: e0159189 (2016)
  7. Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, Schallmoser K, Strunk D, and Majeti R. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nature Medicine, epub (2016)
  8. Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces-Zimmerman MR, Flynn RA, Buenrostro JD, Chan SM, Thomas D, Koenig JL, Hong WJ, Chang HY, and Majeti R. Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. Cell Stem Cell, 17: 675-688 (2015)
  9. Jung N*, Dai B*, Gentles AJ, Majeti R*, and Feinberg A*. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat Communications, 7: 8489 (2015)
  10. McClellan JS*, Dove CG*, Gentles AJ, Ryan CE, and Majeti R. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. P.N.A.S., 112: 4074-4079 (2015)
  11. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, and Majeti R. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 21: 178-184 (2015)
  12. Sinha S, Thomas D, Yu L, Gentles AJ, Jung N, Corces-Zimmerman MR, Chan SM, Reinisch A, Feinberg AP, Dill DL*, Majeti R*. Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood, 125: 316-326 (2015)
  13. Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, Dullin C, Alves F, Andreeff M, Weissman IL, Longaker MT, Schallmoser K, Majeti R, Strunk D. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood, 125: 249-260 (2015)
  14. Corces-Zimmerman MR, Hong W, Weissman IL, Medeiros BC, and Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. P.N.A.S., 111: 2548-2553 (2014)
  15. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL*, Quake SR*, and Majeti R*. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Science Translational Medicine, 4: 149ra118 (2012)
  16. Gibbs KD, Gilbert PM, Sachs K, Zhao F, Blau HM, Weissman IL, Nolan GP*, and Majeti R*. Single cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments. Blood, 117: 4226-4233 (2011)
  17. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, and Majeti R. Prospective separation of normal and leukemia stem cells based on differential expression of TIM3, a human AML stem cell marker. P.N.A.S., 108: 5009-5014 (2011)
  18. Gentles AJ, Plevritis SK, Majeti R*, and Alizadeh AA*. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA, 304: 2706-15 (2010)
  19. Majeti R*, Becker MW*, Tian Q*, Lee M, Yan X, Liu R, Chiang J, Clarke MF, Hood, L, and Weissman IL. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. P.N.A.S., 106: 3396-3401 (2009)
  20. Majeti R*, Park CY*, and Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell, 1:635-645 (2007)